A novel peptide-based pan-influenza A vaccine: A double blind, randomised clinical trial of immunogenicity and safety

Highlights • We have developed a peptide-based pan-influenza A vaccine. • This vaccine was tested in a double-blind placebo-controlled clinical trial. • Results showed a good safety and tolerability profile. • The vaccine was immunogenic in most subjects and showed an anti-viral phenotype.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2015-01, Vol.33 (2), p.396-402
Hauptverfasser: Francis, James N, Bunce, Campbell J, Horlock, Claire, Watson, Jeannette M, Warrington, Steven J, Georges, Bertrand, Brown, Carlton B
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Highlights • We have developed a peptide-based pan-influenza A vaccine. • This vaccine was tested in a double-blind placebo-controlled clinical trial. • Results showed a good safety and tolerability profile. • The vaccine was immunogenic in most subjects and showed an anti-viral phenotype.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2014.06.006